TDSPharm Co

TDSPharm Co FCF per Share

The Free Cash Flow per Share of TDSPharm Co (464280.KQ) as of Oct 26, 2026 is -1,721.47 KRW. In the previous year, Free Cash Flow per Share was 607.29 KRW — a change of -383.47% (lower).

FCF per Share

-1,721.47KRW

YoY

-383.47%

Last updated:

Free Cash Flow per Share of TDSPharm Co is 2025 -1,721.47 KRW. Free Cash Flow per Share of TDSPharm Co was 2024 607.29 KRW. It decreases by -383.47% lower compared to the previous year.

The TDSPharm Co FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2021
657.83 KRW
Jan 1, 2022
482.73 KRW
Jan 1, 2023
631.16 KRW
Jan 1, 2024
607.29 KRW
Jan 1, 2025
-1,721.47 KRW
The TDSPharm Co FCF per Share history
YEARFCF per ShareYoY
-1,721.47KRW-383.47%
607.29KRW-3.78%
631.16KRW+30.75%
482.73KRW-26.62%
657.83KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TDSPharm Co Stock analysis

What does TDSPharm Co do? TDSPharm Co Ltd generates revenue through the manufacture and sale of synthetic drug displays and other finished drugs, as well as medical equipment sales. The company operates in the pharmaceutical manufacturing sector with a focus on synthetic drug displays and finished pharmaceutical products. Its e-commerce business complements traditional sales channels for medical equipment and pharmaceuticals. The primary customers include healthcare providers, hospitals, and medical institutions purchasing synthetic drug displays, finished drugs, and medical equipment. The company's product segments are synthetic drug displays, finished drugs, and medical equipment, with e-commerce serving as an additional sales channel for these segments. TDSPharm Co Ltd's revenue streams are derived from three core product categories: synthetic drug displays, finished drugs, and medical equipment. The company's e-commerce platform facilitates direct sales to healthcare institutions and medical facilities. The business model combines traditional manufacturing with digital sales channels, targeting healthcare providers as the main customer segment. The company's operations are centered on pharmaceutical manufacturing and medical equipment distribution, with e-commerce as a supplementary sales method. The company's primary revenue comes from the sale of synthetic drug displays and finished drugs, which are manufactured and sold directly to healthcare institutions. Medical equipment sales form a secondary revenue stream, while the e-commerce business provides an additional channel for all product categories. TDSPharm Co Ltd targets healthcare providers and medical institutions as its main customer base, with product segments focused on pharmaceutical manufacturing and medical equipment distribution. TDSPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TDSPharm Co stock

Free Cash Flow per Share of TDSPharm Co is -1,721.47 KRW in 2025.

Free Cash Flow per Share of TDSPharm Co changed from 607.29 KRW to -1,721.47 KRW, representing a -383.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share TDSPharm Co since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — TDSPharm Co

All Key Metrics — TDSPharm Co